Fulgent Genetics Stock Surges Amid Broader Market Decline
Fulgent Genetics (FLGT) defied a bearish market trend on Friday, with shares climbing over 8% while major indices slumped. The rally followed a stronger-than-expected Q2 earnings report, where the genetic testing firm posted $82 million revenue (15% YoY growth) and an adjusted profit of $0.07 per share—surpassing analyst estimates of a $0.18 loss.
CEO Ming Hsieh attributed the outperformance to successful diversification efforts across laboratory services and therapeutic development. The company further fueled investor Optimism by raising its 2025 revenue and profit guidance, signaling confidence in its core business segments.